Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 826-833

  Lindholm, Catharina ^a,b   Börjesson Asp, Katharina ^b   Zendjanchi, Kiandokht ^b   Sundqvist, Anna Carin ^b   Tarkowski, Andrej ^a,b   Bokarewa, Maria ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; B lymphocytes; Nephritis; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

ALBUMIN; ANTICONVULSIVE AGENT; AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CLEMASTINE FUMARATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CANDIDIASIS; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; EPILEPSY; FEMALE; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; HYPOCOMPLEMENTEMIA; HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS SYNDROME; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUNG INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SEPSIS; SERUM SICKNESS; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOANTIBODIES; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 44349131653     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Boumpas D, Austin HA III, Vaughan EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
2. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology Oxford 2001;40:205-11.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
4. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
5. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5:564-76.
6. Anolik JH, Campbell D, Felgar RE, et al. The relationship of Fc-gamma-RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
7. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology Oxford 2005;44:1542-5.
8. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
9. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5.
10. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83.
11. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
12. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007;97:228-33.
13. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-6.
14. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
17. Trysberg E, Lindgren I, Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann Rheum Dis 2000;59:236-8.
18. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
19. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72.
20. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.
21. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.
22. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.